– Reuters Citing Source
Related Posts
Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For LP-184 in Advanced Solid Tumors
LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern's AI Platform, RADR®, as a potential therapy for a wide range of advanced solid tumors.LP-184 is
This Analyst With 84% Accuracy Rate Sees Around 24% Upside In Pinterest – Here Are 5 Stock Picks For October From Wall Street’s Most Accurate Analysts
U.S. stocks closed higher on Tuesday, ahead of the Federal Reserve's monetary policy decision. However, all three indices recorded losses last month, with the S&P 500 falling 2.2% and the Dow falling 1.4% for October.
Cowen & Co. Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
Cowen & Co. analyst Tyler Van Buren initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.